Nearly all of the editorial board members of a 150-year-old journal about the molecular underpinnings of medicine and disease have resigned their posts, protesting changes by publisher SpringerNature that they say “jeopardized the future and scholarly legacy of the Journal.”
Back in March, we wrote about the case of Chinese researchers who pulled their 2011 paper in the Journal of Molecular Medicine on ginseng’s potential as a heart remedy because a couple of their images were suspect (duplicated was the word they’d used).
Turns out the journal suffered some collateral damage. JMM also has corrected a “Clinical Implications” article by a group of Canadian researchers about the defunct ginseng paper.
The article, “Use of ginseng to reduce post-myocardial adverse myocardial remodeling: applying scientific principles to the use of herbal therapies,” appeared in the same issue as the original, but for some reason the correction notice appeared online only last week.
A group of researchers from Shangdong, China, has retracted their 2011 paper in the Journal of Molecular Medicine on the heart-protective properties of a substance in ginseng because the article contained dodgy figures.
The paper, “Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor,” was published in December 2010 and cited 15 times since, according to Thomson Scientific’s Web of Knowledge.
An HIV researcher in Germany has run afoul of a number of journals because he duplicated his papers in multiple outlets.
The funny business by Ulrich Hengge earned him a 3-year ban on publishing in two journals, the Journal of Molecular Medicine (JMM) and Cells, Tissues and Organs (CTO). (We’ve written about publishing bans — which appear to be fairly rare — before.)